TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22508814
Drug: Accelerated radiotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiotherapy plus carbogen inhalation and nicotinamide (ARCON) in patients with hypoxic tumors
Study: 17916109
Drug: Lubiprostone 24
Normalized name: LUBIPROSTONE 24MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone 24 mcg twice daily for 4 weeks
Study: 15777101
Drug: Erdosteine suspension
Normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine suspension 175mg/5mL twice daily for 1 month
Study: 10495375
Drug: Finasteride 0.2
Normalized name: MINOXIDIL 5 g in 100 g / FINASTERIDE 0.25 g in 100 g TOPICAL AEROSOL, FOAM [JOHNSON FOAM PRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 0.2 mg/day
Study: 10495375
Drug: Finasteride 0.01
Normalized name: ALFATRADIOL 0.05 g in 100 g / MINOXIDIL SULFATE ESTER 12 g in 100 g / FINASTERIDE 0.01 g in 100 g TOPICAL LIQUID [NR-11]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 0.01 mg/day
Study: 2006245
Drug: Intramuscular scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular scopolamine (0.3 mg, 0.6 mg)
Study: 6643396
Drug: Oral lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lorazepam (2 mg)
Study: 27832140
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CAS and HD-tDCS
Study: 10858333
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin followed by oral azithromycin
Study: 9347429
Drug: Intravenous patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient‐controlled analgesia with morphine (1.0 mg dose, 6 minute lock‐out interval)
Study: 3764625
Drug: Paromomycin (25-35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin (25-35 mg/kg daily in three divided doses for seven days)
Study: 12100776
Drug: Valdecoxib 20
Normalized name: valdecoxib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 20 mg
Study: 12209034
Drug: Valdecoxib 40
Normalized name: valdecoxib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 40 mg
Study: 12700612
Drug: Soy-based meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-based meal replacement (240 g/day, 1200 kcal/day)
Study: 11092464
Drug: Pamidronate +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate + chemotherapy
Study: 28961465
Drug: Pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 2 mg/kg
Study: 28961465
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg
Study: 26115796
Drug: Chemotherapy (investigator-choice)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (investigator-choice)
Study: 15892857
Drug: BB-10153 (0.08,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BB-10153 (0.08, 0.2, 0.6, 1.2, 1.8, 2.4, 3.6, 4.8 mg kg(‐1))
Study: 12473883
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (fistulotomy)
Study: 7657042
Drug: OME +
Normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OME + AMX (high-dose omeprazole 2 x 40 mg and amoxicillin 2 x 1,000 mg for 10 days)
Study: 7657042
Drug: OME (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: OME (high-dose omeprazole 2 x 40 mg)
Study: 2760248
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basic oral hygiene programme without chlorhexidine)
Study: 27941110
Drug: Trained mothers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trained mothers (MUMs) providing rectal artesunate treatment
Study: 27941110
Drug: Community-based health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based health workers (CHWs) providing rectal artesunate treatment
Study: 27941110
Drug: Trained traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trained traditional healers (THs) providing rectal artesunate treatment
Study: 27941110
Drug: Trained community-chosen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trained community-chosen personnel (COMs) providing rectal artesunate treatment
Study: 20184444
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of tramadol
Study: 22089326
Drug: 1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/kg of fentanyl
Study: 9605644
Drug: Granulocyte colony‐stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony‐stimulating factor (G‐CSF)
Study: 11520775
Drug: 3-course treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-course treatment (DAT 2 + 7)
Study: 11520775
Drug: 6-course treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-course treatment (subsequent COAP, DAT 2 + 5, and COAP)
Study: 11520775
Drug: 12-month maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12-month maintenance treatment with low-dose interferon
Study: 10193281
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with ropivacaine 2.5 mg ml‐1
Study: 10193281
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with bupivacaine 2.5 mg ml‐1
Study: 7850820
Drug: Enoximone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (1 mg/kg)
Study: 19719746
Drug: Digoxin (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.01 mg/kg)
Study: 3182329
Drug: 5-FU administered
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU administered at a dose of 300 mg/m2 days 1-5 and 28-32 (Group A)
Study: 3182329
Drug: 5-FU administered
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU administered at a dose of 300 mg/m2 days 1-3 and 28-31 (Group B)
Study: 31573637
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C infusion (50 mg/kg in dextrose 5% in water, n=84)
Study: 27410907
Drug: Atomoxetine (1.0‐1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (1.0‐1.4 mg/kg/day)
Study: 26369655
Drug: Rebamipide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide 0.1 g three times per day for 26 weeks
Study: 16130875
Drug: Total‐etch, two‐step
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total‐etch, two‐step bonding agent
Study: 16130875
Drug: Self‐etch, two‐step
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐etch, two‐step bonding agent
Study: 16130875
Drug: Self‐etch, one‐step
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐etch, one‐step bonding agent
Study: 12103366
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drug (NSAID, Naproxen sodium)
Study: 9918478
Drug: Orlistat, 120
Normalized name: Orlistat, 120 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat, 120 mg 3 times a day
Study: 9918478
Drug: Orlistat, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat, 60 mg
Study: 8787955
Drug: Dexfenfluramine (DF)
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine (DF) 15 mg twice daily
Study: 19803010
Drug: Ceftazidime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (1 to 6 g daily im or iv)
Study: 19803010
Drug: Ceftazidime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (1 g im)
Study: 19803010
Drug: Ceftazidime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (1 and 2 g im 12‐hourly)
Study: 19803010
Drug: Ceftazidime (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (0.5 g 12‐hourly)
Study: 29151416
Drug: Short-term deep
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term deep sedation (midazolam 0.1-0.2 mg/kg, RASS score -4 to -3, duration no more than 12 hours)
Study: 19028780
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (MED), n = 1100
Study: 16880785
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg twice daily (b.i.d.)
Study: 11340825
Drug: Weekly teaching
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly teaching group (1 hour/week for 10 weeks)
Study: 11340825
Drug: Intensive teaching
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive teaching group (2 hours daily for 5 days)
Study: 7957152
Drug: BCAA infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCAA infusion (260 mg x kg‐1 x h‐1 for 70 min)
Study: 3357367
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration before passive upright tilt
Study: 29988969
Drug: internet‐based cognitive‐behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet‐based cognitive‐behavioural therapy (iCBT)
Study: 29072476
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT) administration
Study: 21558574
Drug: GliSODin extract
Normalized name: GliSODin
DrugBank: GliSODin (DB17013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GliSODin extract (500 mg, 2 capsules once daily for 6 weeks)
Study: 17011760
Drug: Alprostadil (prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil (prostaglandin E(1) analogue) administered during operation
Study: 11550161
Drug: 0.15% benzydamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% benzydamine oral rinse, 15 mL for 2 minutes, 4-8 times daily before and during RT, and for 2 weeks after completion of RT.
Study: 11550161
Drug: 0.15% benzydamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% benzydamine oral rinse
Study: 11550161
Drug: Accelerated RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated RT doses (> or = 220 cGy/day)
Study: 8271169
Drug: BSS (Balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSS (Balanced Salt Solution)
Study: 3135572
Drug: Recombinant interferon-gamma
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon-gamma (50 micrograms daily for 20 days, then 50 micrograms every second day up to day 28, subcutaneous injection)
Study: 25911881
Drug: HAIC (Hepatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAIC (Hepatic artery infusion chemotherapy) - 5‐FU 1000 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1, Gemcitabine 1000 mg/m2 on day 1 and 8, starting 3 weeks after operation with intervals of 4 weeks.
Study: 23357657
Drug: Internet-delivered behavioral
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered behavioral activation combined with acceptance and commitment therapy (ACT) for 8 weeks
Study: 15998467
Drug: Epidural blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blood patch (EDBP)
Study: 8697552
Drug: Edrophonium 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.05 mg.kg‐1
Study: 8697552
Drug: Edrophonium 0.1
Normalized name: atropine-edrophonium 0.14 mg-10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.1 mg.kg‐1
Study: 8697552
Drug: Edrophonium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.5 mg.kg‐1
Study: 8697552
Drug: Edrophonium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1.0 mg.kg‐1
Study: 8697552
Drug: Placebo (Edrophonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Edrophonium 0.0 mg.kg‐1)
Study: 2003848
Drug: Medication communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication communication skills program
Study: 2003848
Drug: Medication education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication education program
Study: 6224928
Drug: Biofeedback-assisted relaxation
Normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biofeedback-assisted relaxation and cognitive imagery treatment
Study: 28982774
Drug: Salmeterol 50 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 μg plus fluticasone propionate 500 μg
Study: 28982774
Drug: Salmeterol 50 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 μg
Study: 23653047
Drug: Voriconazole, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole, administered twice daily orally
Study: 23653047
Drug: Intravenous voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous voriconazole
Study: 9757157
Drug: Standard fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fixed-dose zidovudine (500 mg/day)
Study: 22731873
Drug: Aerosolized albuterol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized albuterol (5 mg) every 4 hours for up to 10 days
Study: 22731873
Drug: Aerosolized albuterol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized albuterol (5 mg)
Study: 16500364
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of clomiphene citrate alone (group A, n = 65)
Study: 16500364
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of clomiphene citrate plus hCG (group B, n = 60)
Study: 28850471
Drug: IM morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM morphine
Study: 6537870
Drug: Isolated soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soy protein with 1.6% L‐methionine supplementation
Study: 6537870
Drug: Isolated soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soy protein with 1.1% L‐methionine supplementation
Study: 26937646
Drug: CartiJoint Forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: CartiJoint Forte (two tablets daily for 8 weeks)
Study: 24065463
Drug: AAV1/SERCA2a high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV1/SERCA2a high-dose (1×10(13) DNase-resistant particles)
Study: 24065463
Drug: AAV1/SERCA2a low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV1/SERCA2a low-dose (6×10(11) DNase-resistant particles)
Study: 24065463
Drug: AAV1/SERCA2a mid-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV1/SERCA2a mid-dose (3×10(12) DNase-resistant particles)
Study: 18480923
Drug: NB‐UVB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB‐UVB plus antihistamine
Study: 18480923
Drug: Antihistamine (control)
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine (control)
Study: 15737948
Drug: Hydrocortisone (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (loading dose of 100 mg followed by continuous infusion of 0.18 mg/kg/h for 6 days)
Study: 2142271
Drug: Intracutaneous injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous injections of sterile water
Study: 2142271
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of isotonic saline (placebo)
Study: 699486
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg orally)
Study: 11418517
Drug: Itraconazole oral
Normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution 100 mg bd
Study: 11418517
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B 500 mg tds plus nystatin 2 MU qds
Study: 9596317
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical therapy plus NPPV
Study: 20675729
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical therapy alone
Study: 8042719
Drug: propofol/fentanyl (4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol/fentanyl (4-8 mg.kg‐1.h‐1, 1.2 mg.h‐1)
Study: 8042719
Drug: isoflurane/fentanyl (0.6-1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: isoflurane/fentanyl (0.6-1.2 vol%, 1.2 mg.h‐1)
Study: 8042719
Drug: flunitrazepam/fentanyl (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: flunitrazepam/fentanyl (1.2 mg.h‐1)
Study: 2847928
Drug: Clonidine 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.45 mg daily for three days
Study: 84148
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (800 mg daily)
Study: 7872274
Drug: Sulphasalazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine (2 g daily)
Study: 84148
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of disodium cromoglycate and sulphasalazine
Study: 30671722
Drug: Experimental treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatments (stove exchanges and free stoves)
Study: 29735484
Drug: Inclisiran 200
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 200 mg single-dose
Study: 29735484
Drug: Inclisiran 300
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 300 mg 2-dose
Study: 29735484
Drug: Inclisiran 500
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 500 mg single-dose
Study: 26822398
Drug: Afatinib plus
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib plus vinorelbine (40 mg/day afatinib + 25 mg/m² vinorelbine per week)
Study: 26822398
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus vinorelbine (2 mg/kg trastuzumab per week after 4 mg/kg loading dose + 25 mg/m² vinorelbine per week)
Study: 25707822
Drug: Chemical method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical method (2% R. communis solution)
Study: 22594388
Drug: Back School
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Back School (active therapy, ergonomics, and education)
Study: 11965272
Drug: Control (alternative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (alternative analgesic regimens with general anaesthesia)
Study: 2698241
Drug: Optrex Eye
Normalized name: docosahexaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optrex Eye Lotion (self-administered by irrigation into the left eye three times daily for seven days)
Study: 2698241
Drug: Optrex Eye
Normalized name: docosahexaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optrex Eye Lotion (self-administered in the right eye by 15 patients)
Study: 2698241
Drug: Optrex Eye
Normalized name: docosahexaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optrex Eye Lotion
Study: 183554
Drug: Metronidazole (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (750 mg three times daily for 5 days)
Study: 183554
Drug: Tinidazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (1 g twice daily on 2 consecutive days)
Study: 24725803
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (HI)
Study: 23857221
Drug: Metformin (1.5-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1.5-2.5 g per day)
Study: 20528207
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus low-dose oral contraceptive (ethinyl oestradiol-cyproterone acetate, EE/CA) 850 mg metformin twice a day for three cycles
Study: 19423131
Drug: Alprazolam and
Normalized name: Alprazolam and propranolol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam and investigational compound
Study: 15255788
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (5 micro g kg(‐1) min(‐1))
Study: 29273827
Drug: Eldecalcitol (ELD;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eldecalcitol (ELD; 0.75 μg/day)
Study: 29273827
Drug: 1α hydroxyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1α hydroxyl calcidiol (ALF; 1 μg/day)
Study: 28167659
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg orally once daily until progression or unacceptable toxicity
Study: 10806607
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg) and Metoprolol (50 mg) together
Study: 10180860
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D injection
Study: 1710921
Drug: MOPP-ABVD alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP-ABVD alternating regimen (monthly alternating one cycle of MOPP and one cycle of ABVD)
Study: 19685114
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bupivacaine (group B)
Study: 19638454
Drug: MTX and
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX and SSZ combination therapy
Study: 16990992
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human MBL (rhMBL) 0.01, 0.05, 0.1, and 0.5 mg/kg single intravenous infusions
Study: 16990992
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human MBL (rhMBL) 0.1 or 0.3 mg/kg repeated intravenous infusions at 3-day intervals
Study: 16990992
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human MBL (rhMBL) 0.5 mg/kg single intravenous infusion